ASCO 2025: THP Without Carboplatin Shows Noninferior pCR Rates, Improved Tolerability in HER2+ Early Breast Cancer

by | Jun 9, 2025 | Myeloma News | 0 comments

Source: Pharmacy Times articles

About 64.1% of patients receiving taxane, trastuzumab, and pertuzumab (THP) without carboplatin had pathological complete response rates (pCRs).
Read More

Submit a Comment